RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Consider And Approve Standalone Unaudited Financial Result Along With Limited Review Report For The Quarter Ended December 31, 2020.
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2021 ,inter alia, to consider and approve Standalone unaudited Financial Result along with limited review report for the Quarter ended December 31, 2020. RUBRA MEDICAMENTS LTD. - 531099 - Shareholding for the Period Ended December 31, 2020
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here RUBRA MEDICAMENTS LTD. - 531099 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Chief Financial Officer RUBRA MEDICAMENTS LTD. - 531099 - Closure of Trading Window
Intimation of closure of trading window RUBRA MEDICAMENTS LTD. - 531099 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (LODR), 2015 For The Half Year Ended September 30, 2020
Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (LODR), 2015 for the half year ended September 30, 2020 RUBRA MEDICAMENTS LTD. - 531099 - Unaudited Standalone Financial Results Along With Limited Review Report For The Half Year Ended September 30, 2020
Unaudited Standalone Financial Results along with limited review report for the half year ended September 30, 2020 RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Board Meeting Intimation For Adoption Of Standalone Unaudited Financial Result Along With Limited Review Report For The Quarter Ended September 30, 2020.
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2020 ,inter alia, to consider and approve RUBRA MEDICAMENTS LTD. has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2020,inter alia, to consider and approve adoption of standalone unaudited Financial Result along with limited review report for the Quarter ended September 30, 2020. RUBRA MEDICAMENTS LTD. - 531099 - Reg. 34 (1) Annual Report
Annual Report of the Company for the FY 2019-20 RUBRA MEDICAMENTS LTD. - 531099 - Compliance Certificate Under Regulation 40 (10) Issued By PCS
Compliance certificate under regulation 40 (10) issued by PCS RUBRA MEDICAMENTS LTD. - 531099 - Shareholding for the Period Ended September 30, 2020
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here